Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (289)	2/13/2003 12:37:52 PM
From: Jibacoa	Respond to of 3722

ENZN Is down 9.61% on volume of more than 1.29M (about 1.5x its daily average) while it is making a 52 wks.L <g> It filed its 8K on Tuesday reporting earnings for the 4th Q. Its revenue increase was mainly due to royalties from sales of its PEG-Intron hepatitis C treatment by SGP.(Royalties from its PEG technology products have nearly doubled in its latest 2nd Q.) Although insiders only hold around 1% of the shares, institutions that hold more than 90% of the float have reportedly done some buying lately.<g> The shares had been selling at a PE of less than 12 and ENZN reportedly has about $5 in cash share. The general market is still looking ugly and it doesn't seem like a good time to buy any stocks,and it is not good to try to catch a falling knife <g>, but it doesn't hurt to place ENZN on a watch list while we wait for better times.(If they will eventually come and we can live to see them, which I am starting to have my doubts about.<g>) siliconinvestor.com siliconinvestor.com Bernard